tesamorelin telehealth: Frequently asked questions

Reassess measurement method first. Tesamorelin reduces visceral adipose tissue (deep abdominal fat surrounding organs), not subcutaneous fat, so changes aren't always visible externally. Waist circumference measured at the umbilicus is the most practical clinical marker; if that hasn't decreased by 8–12 weeks, consider: (1) reconstitution errors (improper mixing or storage degrading the peptide), (2) suboptimal injection timing (administering in the morning instead of evening reduces GH pulse alignment), or (3) concurrent caloric surplus negating lipolytic signalling. DEXA or CT imaging quantifies VAT directly if doubt persists.

These are IGF-1-mediated side effects. Not allergic reactions. Check IGF-1 immediately. If IGF-1 is >2.5× baseline, reduce dose to 1mg. If IGF-1 is within target range (1.5–2.0× baseline), the symptoms likely reflect rapid fluid retention rather than true IGF-1 excess. They typically resolve within 4–6 weeks as the body adjusts. NSAIDs can manage symptoms during this adaptation period, but don't mask them with analgesics without checking IGF-1 first.

These are known growth hormone-mediated side effects occurring in 10–15% of patients, caused by fluid retention and soft tissue swelling. Not joint damage. Reduce the dose to 1mg daily for two weeks, then re-escalate to 2mg if symptoms resolve. If symptoms persist at 1mg, discontinue for one week and restart at 1mg with slower titration. Carpal tunnel symptoms (numbness, tingling in the hands, worse at night) typically resolve within four weeks of dose reduction but may require temporary cessation in severe cases.

Waist circumference and waist-to-hip ratio are acceptable surrogates when CT or MRI isn't feasible, but the evidence is weaker. For men, waist circumference >94 cm combined with clinical lipodystrophy (buffalo hump, facial wasting, abdominal protuberance) suggests VAT accumulation sufficient to justify a trial. For women, the threshold is >88 cm. Document the clinical reasoning and set expectations: without imaging, you can't quantify VAT reduction objectively, so treatment duration and continuation decisions rely on patient-reported outcomes and metabolic markers (fasting glucose, HbA1c, triglycerides) rather than imaging endpoints.

Clinical data is mixed. Some EGRIFTA trial subgroups showed modest improvements in fasting glucose and HOMA-IR (a marker of insulin resistance), but other analyses found no significant change or transient worsening during the first 12 weeks. Growth hormone has complex, biphasic effects on glucose metabolism: it acutely increases insulin resistance (lipolysis releases free fatty acids, which compete with glucose for oxidation), but chronic VAT reduction improves insulin sensitivity over time by removing the metabolically harmful fat depot. Don't position tesamorelin as a diabetes treatment. Frame it as a VAT reduction tool that may secondarily benefit metabolic markers if visceral fat was a primary driver of insulin resistance.

Reduce the dose to 1mg daily and recheck IGF-1 in 2 weeks. If IGF-1 normalizes (below 2.0× baseline or within age-adjusted reference range), continue 1mg indefinitely. If IGF-1 remains elevated despite dose reduction, discontinue tesamorelin permanently and evaluate for underlying conditions that amplify GH sensitivity. Untreated hypothyroidism, estrogen therapy, or occult malignancy can all exaggerate IGF-1 response to GHRH stimulation.